相关实验视频

Updated: Jun 25, 2025

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

大脑脊髓液可溶性胰岛素受体水平在阿尔茨海默氏症的疾病

Peter Thomas¹, Manon Leclerc^2,3, Kira Evitts^4,5

¹Geriatric Research Education and Clinical Center Veterans Affairs Puget Sound Health Care System Seattle Washington USA.

Alzheimer's & dementia (Amsterdam, Netherlands)

|May 27, 2024

概括

大脑脊髓液中的可溶性胰岛素受体 (sIR) 水平与阿尔茨海默病生物标志物和认知功能相关. 神经元和星球细胞有助于sIR生成,这表明在AD病变发生过程中发挥了作用.

科学领域:

神经科学是一个神经科学.
内分泌学在内分泌学.
生物化学生物化学

背景情况:

阿尔茨海默病 (AD) 的特点是大脑对胰岛素的抵抗和缺乏.
胰岛素耐药性与胰岛素受体 (IR) 相关,可以分裂形成可溶性IR (sIR).

研究的目的:

在阿尔茨海默病 (AD) 中研究可溶性胰岛素受体 (sIR) 的水平和细胞起源.
探索sIR,粉样β (Aβ) 和AD患者的认知功能之间的关系.

主要方法:

从AD频谱中两个独立的个人队伍中测量了脑脊液 (CSF) 中的sIR水平.
使用人类细胞系,包括神经元和星球细胞,研究了sIR生产的细胞来源.

主要成果:

在AD诊断组中,CSFsIR水平没有显著差异.
脑脊髓中SIR水平与粉样β (Aβ) 42和Aβ40水平呈正相关.
CSF sIR水平与认知表现有负相关性.
表达粉样蛋白前体蛋白的瑞典突变的神经元产生了更多的sIR.
星球细胞在对炎症和胰岛素刺激的反应中释放sIR.

结论:

这些发现表明,sIR与AD病理和认知衰退有关.
需要进一步的研究来阐明sIR生成的具体机制及其在AD中的功能作用.

关键词:

阿尔茨海默氏症的疾病是阿尔茨海默氏症.粉样蛋白β 42 粉样蛋白β 42 是一种认知认知认知胰岛素受体的胰岛素受体可溶性溶性溶性的

更多相关视频

Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

Absolute Quantification of Aβ_1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

Published on: March 21, 2017

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...